SERDA Therapeutics funding news – Amsterdam-based SERDA Therapeutics Secures €2Million in Funding

SERDA Therapeutics is developing a proprietary, best-in-class, fast, and effective product for wound debridement in the treatment of severe burn injuries and chronic ulcers, such as pressure ulcers, open leg, and diabetic foot ulcers.

Gabor Heltovics, CEO of SERDA said, “Our mission at SERDA is to revolutionize wound debridement and improve the lives of those suffering from such conditions. Our enzymatic debridement technology is being developed to combine exceptional long-term stability with fast removal of damaged tissue, significantly reducing healing time and discomfort. This approach would not only speed up recovery but also improve the quality of life for patients dealing with chronic conditions and burn injuries,”.

Globally, millions suffer from chronic and burn wounds, conditions exacerbated by an aging population and an increasing prevalence of diabetes. The traditional methods for managing such wounds, including surgical and enzymatic debridement, are often costly, painful, and/or inefficient.

Read also - Ciphr acquisition news – UK-based Ciphr Acquired Shape Payroll

Jaap Haemers, Investment Manager at NLC said, “SERDA’s innovative approach to wound care has the potential to significantly reduce both the healthcare burden of chronic wounds and the personal impact on patients. We are excited to support SERDA as they move closer to bringing this vital technology to market, As SERDA Therapeutics continues to move towards commercialization, the company has initiated a Phase 1 clinical trial to be followed by a Phase IIa study on burn wounds later this year. This trial, supported by the U.S. The Army’s medical research division marks an important step in bringing SERDA’s gentle and effective wound care solutions closer to those who need them most."

About SERDA Therapeutics

SERDA Therapeutics is a leader in developing innovative treatments for severe wound care. With an aging population and increasing diabetes prevalence, effective wound treatment is critical. Traditional debridement methods—surgical, mechanical, and enzymatic—are often painful and inefficient.

SERDA’s solution is a hydrogel which offers an enzymatic wound debrider that shows fast speed of debridement, ease of use, high level of stability, and low-moderate irritation potential.